Lynx1 Capital Management LP: C4 THERAPEUTICS INC (CCCC): Quarterly 13F Position History
As of Q1 2026, Lynx1 Capital Management LP reported 6,998,902 shares of C4 THERAPEUTICS INC (CCCC), worth $18.4M and representing 2.9% of its 13F equity book. Quarter-over-quarter share count change: 99,231 (-1.4%) . The position first appeared in Q3 2023 and has been disclosed across 11 13F-HR filings in Pactolio's tracked window.
- 6,998,902Shares Held (Latest Filing)
- $18.4MReported Market Value (Latest Filing)
- 2.9%Portfolio Weight (% of 13F Equity Book)
- 99,231Quarter-over-Quarter Share Change
- +$4.8MQuarter-over-Quarter Value Change
- 7,098,133Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 11 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 6,998,902 | 99,231 | -1.4% | $18.4M | 2.9% | $2.6 |
| Q4 2025 | 7,098,133 | 0 | — | $13.6M | 2.7% | $1.9 |
| Q3 2025 | 7,098,133 | 0 | — | $15.8M | 3.2% | $2.2 |
| Q2 2025 | 7,098,133 | 0 | — | $10.2M | 2.9% | $1.4 |
| Q1 2025 | 7,098,133 | +245,389 | +3.6% | $11.4M | 4.1% | $1.6 |
| Q4 2024 | 6,852,744 | 27,783 | -0.4% | $24.7M | 9.2% | $3.6 |
| Q3 2024 | 6,880,527 | 0 | — | $39.2M | 13.9% | $5.7 |
| Q2 2024 | 6,880,527 | +3,245,865 | +89.3% | $31.8M | 11.5% | $4.6 |
| Q1 2024 | 3,634,662 | +500,266 | +16.0% | $29.7M | 7.7% | $8.2 |
| Q4 2023 | 3,134,396 | +2,115,166 | +207.5% | $17.7M | 7.0% | $5.7 |
| Q3 2023 | 1,019,230 | — | — | $1.9M | 1.3% | $1.9 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did Lynx1 Capital Management LP first disclose a CCCC position in 13F-HR filings?
Lynx1 Capital Management LP first reported C4 THERAPEUTICS INC (CCCC) on its 13F-HR filing for the period ending 2023-09-30 (Q3 2023). The position has appeared on 11 reported quarters within Pactolio's tracked window.
What was Lynx1 Capital Management LP's most recent quarter-over-quarter share-count change in CCCC?
Between Q4 2025 and Q1 2026, Lynx1 Capital Management LP reduced its CCCC position by 99,231 shares (-1.4%), leaving 6,998,902 shares at a market value of $18.4M.
Does the implied price-per-share represent Lynx1 Capital Management LP's cost basis in CCCC?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.